Therapeutic vaccine against Alzheimer's disease

The first phase of the clinical trial of the vaccine against Alzheimer's disease has started

YouCure.me based on the materials of the company's press release:
AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's diseaseClinical trials of the first therapeutic vaccine against Alzheimer's disease – the biological preparation ACI-35 – were started by the biotech company AC Immune (Switzerland).

The main goal of the first phase of clinical trials is to establish the safety of the use of a new drug.

The innovative mechanism of action of the experimental vaccine is aimed at the formation of specific antibodies to phosphorylated tau proteins, which are found in the brain in Alzheimer's disease. In preclinical studies conducted earlier, it was found that the biological preparation ACI-35 effectively reduces the level of tau protein.

Alzheimer's disease is the most common form of dementia – acquired dementia, with the development of which there is a loss of long-term memory. The average life expectancy after diagnosis is about seven years.

At the moment, there is no effective method of treating Alzheimer's disease, and all available therapies can only slightly affect the symptoms of the disease. Pharmacological companies have presented more than a hundred experimental drugs in recent years, but all of them have failed in trials.

Portal "Eternal youth" http://vechnayamolodost.ru15.01.2014